Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival

Acta Oncologica

Volumn 49, Issue 8, 2010, Pages 1283-1287

  Offersen, Birgitte V ^a   Knap, Marianne M ^a   Horsman, Michael R ^a   Verheijen, Jan ^b   Hanemaaijer, Roeland ^b   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GELATINASE B;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER MORTALITY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CREATININE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 77958170682     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.509109     Document Type: Article

References (13)

1. Prout GR, Jr., Griffin PP, Shipley WU. Bladder carcinoma as a systemic disease. Cancer 1979;43:2532-9.
2. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010;141:52-67.
3. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34.
4. Sier CF, Casetta G, Verheijen JH, Tizzani A, Agape V, Kos J, et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: A comparison with clinically used tumor markers. Clin Cancer Res 2000;6:2333-40.
5. Hermanek P, Sobin LH. Urology and the TNM classification. Lancet 1988;2:1495.
6. Verheijen JH, Nieuwenbroek NM, Beekman B, Hanemaaijer R, Verspaget HW, Ronday HK, et al. Modified proenzymes as artificial substrates for proteolytic enzymes: Colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem J 1997;323:603-9.
7. Hanemaaijer R, Visser H, Konttinen YT, Koolwijk P, Verheijen JH. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: Saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol 1998;17:657-65.
8. Wittlinger M, Rödel CM, Weiss C, Krause SF, Kühn R, Fietkau R, et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: Transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol 2009;93:358-63.
9. Wright P, Redpath AT, Høyer M, Grau C, Muren LP. The normal tissue sparing potential of adaptive strategies in radiotherapy of bladder cancer. Acta Oncol 2008;47:618-32.
10. Fiorino C, Valdagni R, Rancati T, Sanguineti G. Dosevolume effects for normal tissues in external radiotherapy: Pelvis. Radiother Oncol 2009;93:153-67.
11. Angenete E, Oresland T, Falk P, Breimer M, Hultborn R, Ivarsson ML. Preoperative radiotherapy and extracellular matrix remodelling in rectal mucosa and tumour matrix metalloproteinases and plasminogen components. Acta Oncol 2009;48:1144-51.
12. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
13. Offersen BV, Knap MM, Marcussen N, Horsman MR, Hamilton-Dutoit S, Overgaard J. Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis. Br J Cancer 2002;87:1422-30.